For Medical Professionals
A Trusted Referral Source
Rocky Mountain Cancer Centers (RMCC) is the largest multidisciplinary practice on the Colorado Front Range dedicated solely to providing state-of-the-art care for patients with cancer and diseases of the blood. The RMCC team is composed of physicians who specialize in medical, radiation, and surgical oncology, hematology, pathology, and palliative care and work collaboratively to provide high quality, evidence-based cancer care.
At RMCC, our search for new treatments is relentless. Our drive to provide superior care runs deep. And our fight against cancer is personal. Our independent, physician-led practice is known for delivering clinical excellence combined with unmatched personal and emotional support in neighborhoods through the front range. At RMCC:
- Renowned experts aggressively attack cancer with every possible strategy.
- Our nationally recognized clinical trials team is located here on the front range and engaged in a passionate search for innovative treatments.
RMCC implements a widely used methodology known as Net Promoter Score, which allows for the real-time evaluation of service quality and patient satisfaction. By industry standards, a score of 75 percent or above is considered high. Consistently scoring above 80 percent, RMCC ranks among the highest recorded in any industry.
At its heart, our approach to cancer care is simple - to surround our patients with everything they need so they can focus on what matters most: beating cancer.
Why Rocky Mountain Cancer Centers?
Since 1992, Rocky Mountain Cancer Centers has defined the standard of cancer treatment, treating more adult cancer patients than any other organization in Colorado. Our independent, community-based model of cancer care means that patient-centered, evidence-based treatment is always close to home.
We are an independent, physician-owned practice.
This means that we have the freedom to make the care decisions that benefit our patients and their families – not health systems.
We offer unmatched experience, expertise, and access.
- RMCC providers have a combined 150+ years of experience.
- There are more than 500 clinical trials available to your patients.
- We provide our physicians’ cell phone numbers to referring providers so that you can easily reach us by phone with any questions or urgent cases.
We uphold a lower cost of care.
We are committed to providing unmatched quality care while keeping patients’ cancer costs low. We achieve this through our participation in the Center for Medicare and Medicaid’s Oncology Care Model. For every dollar spent in the office of an independent oncologist, it’s estimated by the federal government the spend will be $1.80 with an oncologist employed by a hospital system. It doesn’t mean you receive lesser care at RMCC. It means patients receive the very best care that happens to be at a better price. We decrease the total cost of cancer care by:
- Utilizing fiscally responsible drug strategies.
- We have our own pharmacy with staff that specializes in oral oncolytics.
- We offer diagnostic imaging services.
- Utilizing Navigating Care; a remote symptom, side-effect, and medication management system.
- As a member of The US Oncology Network, our physicians maintain their independence, but get the support of a management company that has deep expertise in oncology practice management and value-based care delivery.
We provide increased patient care quality.
- Communicating and coordinating care with all providers.
- Measuring patient satisfaction and creating ongoing strategies to improve the patient experience.
- Providing pain assessment and management.
- Offering additional patient support services (financial, clinical, nutrition, weight loss, smoking cessation).
We utilize treatment pathways for the most successful outcomes.
Value Pathways powered by NCCN™ (National Comprehensive Cancer Network) are treatment pathways that highlight evidence-based treatment options based on efficacy, toxicity and an evaluation of financial impact to patient and payer (Medicare reimbursement). The pathways are a refinement of the NCCN Guidelines and the result of combined efforts through a collaboration between three organizations: NCCN, McKesson and The US Oncology Network. Value Pathways powered by NCCN is a shorter, distilled list of treatment choices that support the delivery of high-quality, cost-effective patient care.
Innovative Clinical Trials
Clinical Research Trials available to patients to evaluate new treatments and combinations of treatments.
Diagnostic Imaging Services includes CT and PET/CT scanners in many clinics and our Mobile PET/CT Coach.
Pathology and Lab Services
On-Site Laboratories providing rapid turnaround for many tests including:
- Complete Blood Count (CBC)
- Chemistry Tests
- Clotting Tests
- Tumor Markers
Medically-Integrated Dispensing Pharmacy ready to fill oncolytic and supportive care prescriptions with a dedicated team.
Cancer Screening Guidelines
Colon Cancer [NEW UPDATES]
Age 21: Testing may be recommended if you have a higher than average risk of colon cancer.
Age 45-75: People at average risk (are in good health and with a life expectancy of more than 10 years) should continue regular colorectal cancer screenings.
Age 76-85: The decision to be screened should be based on patient preference, life expectancy, overall health, and prior screening history.
Age 86 and over: Should no longer get colorectal cancer screening.
HIGH RISK: People who are at an increased or high risk for colorectal cancer might need screening before the age of 45, be screened more often, and/or get specific tests. Risk factors include:
- A personal history or a strong family history of colorectal cancer or certain types of polyps
- A personal history of inﬂammatory bowel disease (ulcerative colitis or Crohn’s disease)
- A known family history of a hereditary colorectal cancer syndrome such as familial adenomatous polyposis (FAP) or Lynch syndrome (also known as hereditary non-polyposis colon cancer or HNPCC)
- A personal history of radiation to the abdomen (belly) or pelvic area to retreat a prior cancer
- Highly sensitive fecal immunochemical test (FIT) every year
- Highly sensitive guaiac-based fecal occult blood test (gFOBT) every year
- Multi-targeted stool DNA test (mt-sDNA) every three years
- Colonoscopy every 10 years for average risk; more frequent based on personal and family history or if pathology identiﬁed
- CT colonography (virtual colonoscopy) every five years; more frequently if pathology identiﬁed
- Flexible sigmoidoscopy (FSIG) every five years; more frequently if pathology identiﬁed
What’s New? The age recommendation for screening has changed from 50 to 45 years old, April 2021.
HIGH RISK: Patients who are considered high risk should have an MRI/MRCP and/or endoscopic ultrasound annually, starting at age 50 (or 10 years prior to the earliest diagnosis in the family). Risk factors include:
- Certain gene mutations such as ATM, BRCA1, BRCA2, Lynch Syndrome, and others
- Family history of pancreatic cancer in two or more ﬁrst-degree relatives
- Family history of pancreatic cancer in three or more ﬁrst and/or second-degree relatives
Lung Cancer [NEW UPDATES]
Age 50-80: Annual lung cancer screening with a low-dose CT scan (LDCT) if your patients are:
- In fairly good health
- A current or former smoker (within the past 15 years)
- Have at least a 20 pack-year smoking history
What’s New? As of March 2021, the U.S. Preventive Services Task Force (USPSTF) revised the recommended ages and pack-years for lung cancer screening. It expanded the age range from 50-80 years (previously 55 to 80 years) and reduced the pack-year history to 20 pack-years of smoking (previously 30 pack-years).
Female Breast Cancer [NEW UPDATES]
Age 40-74: Start screening with mammogram annually.
Age 75 and over: Should continue with mammograms if their overall health is good, and they have a life expectancy of 10 or more years.
HIGH RISK: Women who are high risk for breast cancer should get a breast MRI and a mammogram annually, typically starting 10 years prior to earliest breast cancer diagnosis in the family. Risk factors include:
- A lifetime risk of breast cancer of about 20% or greater, according to risk assessment tools that are based mainly on family history (i.e. Tyrer Cuzick)
- A known BRCA1 or BRCA2 gene mutation (based on having had genetic testing) or other genetic predisposition for breast cancer
- A ﬁrst-degree relative (parent, brother, sister, or child) with BRCA1 or BRCA2 gene mutation, but patient has not had genetic testing themselves
- Previous radiation therapy to the chest when they were between the ages of 10 and 30 years
The American Cancer Society recommends against MRI screening for women whose lifetime risk of breast cancer is less than 15%.
What’s New? American College of Radiology (ACR) and Society of Breast Imaging (SBI) now recommend that ALL women should be evaluated for breast cancer risk no later than age 30 (review personal and family history and complete risk-assessment).
Cervical Cancer [NEW UPDATES]
Age 21-24: No screening needed.
Age 25-65: Women should have an HPV test every five years. If HPV testing is not available, women can get screened with an HPV/PAP co-test every five years, or a PAP test every three years.
Age 65 and older: No screening needed if a series of prior tests were normal.
What’s New? There are two major diﬀerences from previous guidelines:
- The starting age for screening has moved to slightly older (from starting at age 21 to age 25).
- HPV testing recommendations have changed.
Start discussions with men about their screening options:
Age 40-49: No screening needed.
Age 50-69: Consider screening with a PSA for average-risk patients. The decision to screen with PSA should be based on patient preference, family history, and current health.
Age 70 and older OR any man with less than 10-15 years life expectancy: Should not be screened for prostate cancer routinely.
HIGH RISK: Consider screening with PSA in high-risk populations and African Americans with a positive family history starting at age 40. Risk factors include:
- Men with a ﬁrst-degree relative (father or brother) who had prostate cancer at an early age (younger than age 65)
- Men with a genetic predisposition for prostate cancer (BRCA1/2 positive or other genes)